Catalyst Pharmaceuticals, Inc. (CPRX) News
Filter CPRX News Items
CPRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CPRX News Highlights
- For CPRX, its 30 day story count is now at 3.
- Over the past 28 days, the trend for CPRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RARE, MG and LINK are the most mentioned tickers in articles about CPRX.
Latest CPRX News From Around the Web
Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.
Earnings Preview: Catalyst Pharmaceutical (CPRX) Q1 Earnings Expected to DeclineCatalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release first quarter 2021 financial results after market close on Monday, May 10, 2021. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, May 11, 2021 to discuss the financial results and to provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in l... |
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Catapults 28% Though Its Price And Business Still Lag The MarketThe Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) share price has done very well over the last month, posting an... |
Catalyst Pharma To Buy Back $40M In Stock; Shares Gain Pre-MarketShares of Catalyst Pharma rose more than 3% in the pre-market session after the commercial-stage biopharmaceutical company announced its stock repurchase program of up to $40 million. Catalyst Pharma (CPRX) intends to use existing cash on hand to fund the share repurchase program. Catalyst Pharma CEO Patrick J. McEnany said, “We believe that our strong balance sheet, earnings power and borrowing capability have us well-positioned to successfully execute both on our recently announced strategic initiative to expand our product and pipeline portfolio of therapies to treat other rare diseases and on this share repurchase program.” (See Catalyst Pharma stock analysis on TipRanks) Last week, the company reported 4Q results. |
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase ProgramCORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that its Board of Directors has authorized the repurchase of up to $40 million of shares of Catalyst's outstanding common stock. "This share repurchase program reflects our confidence in the long-term outlook for the Company, including our ability to continue to generate strong cash flow," said Patrick J. McEnany, the Company's Chairman and Chief Executive Officer. "We believe that our strong balance sheet, earnings power and borrowing capability have us well-positioned to... |
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is InterestingIt's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks... |
Top Biotech Stocks for Q2 2021The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline. |
Catalyst Pharma 4Q Revenue, Earnings Outperform EstimatesCatalyst Pharmaceuticals delivered a better-than-expected 4Q performance, driven by higher sales for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS) patients. Shares of the commercial stage biopharmaceutical company rose about 1.5% in the extended trading session on Monday. Catalyst Pharma’s (CPRX) revenue, comprised primarily of Firdapse sales, increased by $0.9 million year-over-year to hit $31 million, topping analysts’ estimates of $30.35 million. The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share. The company’s Chairman and CEO Patrick J. McEnany said, “We are extremely pleased with our continued commercial execution of the Firdapse launch during 2020. |
Catalyst Pharmaceuticals Earnings Report: Here’s what to expect from Stock market Insights & financial analysisCatalyst Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by… |
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings GrowthCatalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |